Komori
Financial results presentation4912Lion CorporationMaterials and Chemicals

Financial Results Presentation for the Third Quarter of the Fiscal Year Ending December 2026

For January to September 2026, revenue and business profit increased due to growth in the overseas business and higher value-added products and price increases, and the business profit margin also improved. However, profit for the quarter attributable to owners of the parent decreased because of higher tax expenses associated with the transfer of shares in a subsidiary engaged in the chemicals business.

Worth reading
68In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
33.8
¥100 million (year-on-year increase in business profit)
Wording
Definitive
How definitive the wording is.

Contents of this document

Financial results presentationFiscal year ending December 2026: third quarter13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,254.1 100 million+6.7%
Operating profit¥312.8 100 million+12.4%
Net income¥179.7 100 million -13.6%profit for the quarter attributable to owners of the parent
Operating profit margin9.6 %
Results for the three months of the current quarterThe company disclosed the factors behind the change in business profit for July to September alone: volume effects and other factors, +¥1.6 billion; higher value-added products and price increases, +¥0.5 billion; raw material prices, -¥3.2 billion; cost reductions, +¥1.0 billion; competition-related expenses and other factors, +¥1.1 billion; and other expenses, -¥1.0 billion. Quarterly revenue and total profit for the three-month period are Not disclosed.
Full-year earnings forecast
Net Sales
¥4,300 100 million
Business profit
¥350 100 million
Operating profit
¥400 100 million
Profit for the year attributable to owners of the parent
¥250 100 million
EBITDA
¥550 100 million
ROIC
7 %
ROE
7.7 %
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales75.7 %
Business profit73.4 %
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
On track to achieve the full-year earnings targets
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Volume and mix effects, etc.34
Premiumization and price increases109
Impact of raw material prices-47
Cost reductions21
Changes in competitive costs-20
Change in other expenses-63
Foreign-Exchange Volatility53
Business Portfolio Transformation29
Logistics efficiency gains7
Higher personnel expenses-13
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Specific assumptions for exchange rates, raw material prices, interest rates and other factors are Not disclosed. Domestic shipping price increases will be implemented from October 2026.
New initiatives
  • Strategic partnership with FDI (FDI World Dental Federation). Participation in World Oral Health Day from 2027
  • Launch of the oral healthcare business in Vietnam
  • Repurchase and cancellation of treasury shares for a total amount of ¥20 billion, with a maximum of 16 million shares
  • Strengthen high-value-added products and brand initiatives in Japan and overseas
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥408 100 million
    Year on year against the same period last year+14.6%
  • EBITDA margin12.5 %
    Year on year against the same period last year+0.8P
  • Oral healthcare revenue growth rate10.7 %
    Year on year against the same period last yearYear on year
  • Overseas business revenue growth rate19.4 %
    Year on year against the same period last yearYear on year
  • Improvement in overseas business EBITDA margin3.2 pt
    Year on year against the same period last yearCompared with 2024
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Japanese household products marketSales value: 105; units sold: 99; average unit price: 106 (year-on-year)
OTC pharmaceutical marketSales value: 101; units sold: 98; average unit price: 103 (year-on-year)
Segment results
Consumer Products Business
Net Sales1,876.8
Revenue_unit¥100 million
Revenue_yoy_pct0.9
Business profit164.4
Operating profit_unit¥100 million
Business profit_yoy_pct3.7
Industrial products
Net Sales360.7
Revenue_unit¥100 million
Revenue_yoy_pct-16.9
Business profit17.2
Operating profit_unit¥100 million
Business profit_yoy_pct-24.8
Overseas Business
Net Sales1,550.1
Revenue_unit¥100 million
Revenue_yoy_pct19.4
Business profit99.5
Operating profit_unit¥100 million
Business profit_yoy_pct77.8
Other
Net Sales63.9
Revenue_unit¥100 million
Revenue_yoy_pct-17.4
Business profit0.3
Operating profit_unit¥100 million
Medium-term management plan targets
Vision2030 2nd STAGE
2027 targetEBITDA margin of over 13%
Oral healthcare revenue growth rateCAGR of approximately 8%
Overseas revenue growth rateCAGR of approximately 10%
Overseas EBITDA marginApproximately +2 percentage points
General consumer products EBITDA marginApproximately +3 to 5 percentage points
Financial targets
ROIC
Target value7 %
ROE
Target value7.7 %
Market Size / Share
Year-on-year and quarter-on-quarter changes were disclosed for major categories in Japan and overseas. Market share is Not disclosed.
Annual Dividend
34 Yen per share
BreakdownInterim and year-end breakdown: Not disclosed
Payout ratio
37.6
Acquisition of treasury shares
¥20.0 billion total
Number of Shares16 million shares (maximum)
PeriodNovember 2026 to April 2027
MethodPurchases through ToSTNeT-3 and market purchases on the Tokyo Stock Exchange
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredFiscal year ending December 2026: third quarter
Net Sales¥3,254.1 100 million (YoY +6.7%)
Operating profit¥312.8 100 million (YoY +12.4%)
Net income¥179.7 100 million (profit for the quarter attributable to owners of the parent) (YoY -13.6%)
Operating profit margin9.6 %
Results for the three months of the current quarterThe company disclosed the factors behind the change in business profit for July to September alone: volume effects and other factors, +¥1.6 billion; higher value-added products and price increases, +¥0.5 billion; raw material prices, -¥3.2 billion; cost reductions, +¥1.0 billion; competition-related expenses and other factors, +¥1.1 billion; and other expenses, -¥1.0 billion. Quarterly revenue and total profit for the three-month period are Not disclosed.
Full-year earnings forecastNet Sales ¥4,300 100 million / Business profit ¥350 100 million / Operating profit ¥400 100 million / Profit for the year attributable to owners of the parent ¥250 100 million / EBITDA ¥550 100 million / ROIC 7 % / ROE 7.7 %
Progress against full-year forecastNet Sales 75.7 % / Business profit 73.4 %
Self-assessment against the planOn track to achieve the full-year earnings targets
Segment resultsConsumer Products Business Net Sales 1,876.8 / Revenue_unit ¥100 million / Revenue_yoy_pct 0.9 / Business profit 164.4 / Operating profit_unit ¥100 million / Business profit_yoy_pct 3.7 / Industrial products Net Sales 360.7 / Revenue_unit ¥100 million / Revenue_yoy_pct -16.9 / Business profit 17.2 / Operating profit_unit ¥100 million / Business profit_yoy_pct -24.8 / Overseas Business Net Sales 1,550.1 / Revenue_unit ¥100 million / Revenue_yoy_pct 19.4 / Business profit 99.5 / Operating profit_unit ¥100 million / Business profit_yoy_pct 77.8 / Other Net Sales 63.9 / Revenue_unit ¥100 million / Revenue_yoy_pct -17.4 / Business profit 0.3 / Operating profit_unit ¥100 million
Breakdown of Factors Affecting the ChangeVolume and mix effects, etc. 34 / Premiumization and price increases 109 / Impact of raw material prices -47 / Cost reductions 21 / Changes in competitive costs -20 / Change in other expenses -63 / Foreign-Exchange Volatility 53 / Business Portfolio Transformation 29 / Logistics efficiency gains 7 / Higher personnel expenses -13
Key KPIsIndicator name EBITDA / Value ¥408 100 million / Year on year against the same period last year ¥14.6 100 million, Indicator name EBITDA margin / Value 12.5 % / Year on year against the same period last year +0.8P, Indicator name Oral healthcare revenue growth rate / Value 10.7 % / Year on year against the same period last year Year on year, Indicator name Overseas business revenue growth rate / Value 19.4 % / Year on year against the same period last year Year on year, Indicator name Improvement in overseas business EBITDA margin / Value 3.2 pt / Year on year against the same period last year Compared with 2024
Unit price and quantity metricsJapanese household products market Sales value: 105; units sold: 99; average unit price: 106 (year-on-year) / OTC pharmaceutical market Sales value: 101; units sold: 98; average unit price: 103 (year-on-year)
Assumptions Underlying the Business OutlookSpecific assumptions for exchange rates, raw material prices, interest rates and other factors are Not disclosed. Domestic shipping price increases will be implemented from October 2026.
Medium-term management plan targetsVision2030 2nd STAGE 2027 target EBITDA margin of over 13% / Oral healthcare revenue growth rate CAGR of approximately 8% / Overseas revenue growth rate CAGR of approximately 10% / Overseas EBITDA margin Approximately +2 percentage points / General consumer products EBITDA margin Approximately +3 to 5 percentage points
Financial targetsROIC Target value 7 % / ROE Target value 7.7 %
Annual Dividend34 Yen per share
Payout ratio37.6
Acquisition of treasury sharesAmount ¥20.0 billion total / Number of Shares 16 million shares (maximum) / Period November 2026 to April 2027 / Method Purchases through ToSTNeT-3 and market purchases on the Tokyo Stock Exchange
Market Size / ShareYear-on-year and quarter-on-quarter changes were disclosed for major categories in Japan and overseas. Market share is Not disclosed.
New initiativesStrategic partnership with FDI (FDI World Dental Federation). Participation in World Oral Health Day from 2027, Launch of the oral healthcare business in Vietnam, Repurchase and cancellation of treasury shares for a total amount of ¥20 billion, with a maximum of 16 million shares, Strengthen high-value-added products and brand initiatives in Japan and overseas
Items this document does not state (9)
Ordinary incomeGross Profit MarginSelling, general and administrative expensesNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Growth in overseas business revenue and higher gross profit from higher value-added products and price increases in Japan and overseas more than offset the impact of surging raw material prices. The decrease in quarterly profit was due to higher tax expenses associated with the transfer of shares in a subsidiary engaged in the chemicals business.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Presentation for the Third Quarter of the Fiscal Year Ending December 2026 | Lion Corporation (4912) timely disclosure | Komori